Doctorly GmbH raised $10 million in a series A funding round to revamp the German health care sector, giving medical staff new tools to eliminate disk operating systems (DOS).
Newco Teitur Trophics ApS has raised €28 million (US$30.1 million) in a series A with which it will lay out a new route to targeting sortilin in the treatment of neurodegenerative diseases. The company is targeting the sortilin-related Vps10p domain containing receptor, which plays a role in regulating a number of pathways involved in the control of neuronal viability and function.
Teitur Trophics ApS, a spinout from Aarhus University seeded by the Bioinnovation Institute in 2020, has completed a €28 million (US$30.1 million) series A financing. Teitur has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function, and these peptides have the potential to treat a broad range of neurodegenerative diseases.
Siyi Intelligence Technology Co. Ltd. raised nearly $15 million in a series A funding round to speed up the development of its smart rehabilitation products and of its neurorehabilitation solutions and build a digital rehabilitation service platform.
Precision oncology startup Prana Thoracic Inc. closed a $3 million series A financing round aimed at advancing its minimally invasive lung tissue excision device for early treatment of lung cancer. The series A funds and a prior $3 million award from the Cancer Prevention & Research Institute of Texas are earmarked for product development and to support first-in-human clinical studies.
Rapport Therapeutics Inc. launched with $100 million in series A funding and ambitious plans to bring a hitherto unprecedented level of precision to therapies for neurological disease. Although the Boston-based company is new to the world, its underlying platform has been a decade in the making, and it already has one clinical-stage asset, which is in development for seizure disorders. It is currently undergoing a phase I trial.
Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in 2019, Immorna develops therapeutics and vaccines based on its RNA platforms, including conventional, self-replicating and circular RNA.
Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in 2019, Immorna develops therapeutics and vaccines based on its RNA platforms, including conventional, self-replicating and circular RNA.
With a $200 million oversubscribed and upsized series A round completed, Cargo Therapeutics Inc. will advance its autologous CD22 chimeric antigen receptor (CAR) T-cell therapy, CRG-022, which has breakthrough therapy designation in the U.S. “The proceeds are critical for us,” said Gina Chapman, CEO of San Mateo, Calif.-based Cargo. “We will demonstrate manufacturability this year and kick off the pivotal phase II.”
Armed with $193 million in combined series A and B rounds, Aera Therapeutics aims to address current challenges with delivering gene-based therapies via a self-assembling human-derived protein platform it has in-licensed from a well-known Harvard scientist’s lab.
RSS
